FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study. PMID 41888707 · BMC Cancer · 2026-Mar-26 The record describes a randomized study of an exploratory biomarker (monocyte ratio) for predicting response to metastasis-directed therapy (SBRT) in prostate cancer. It is an oncology human randomized trial with original results, but it does not meet key eligibility criteria: 1) The intervention is not drug-containing (compares iADT alone vs. iADT+SBRT, where SBRT is radiation, not a drug); 2) The endpoint is biochemical response/progression, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc.; 3) It is a subgroup/biomarker analysis, not a primary report of a Phase III/IIIb or II/III drug trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study. PMID 41888696 · BMC Cancer · 2026-Mar-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031). PMID 41888667 · J Neurodev Disord · 2026-Mar-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prospective randomised trial comparing thermal ablation With laparoscopic Adrenalectomy as an alternatiVE treatment for unilateral asymmetric primary aldosteronism: a protocol for the WAVE trial. PMID 41887640 · BMJ Open · 2026-Mar-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Associations between perceived neighborhood environment and physical activity among breast cancer patients engaged in a physical activity program concomitant to cancer treatment: cross-sectional and longitudinal analyses in the DISCO trial (DiscoSpace). PMID 41882725 · Int J Behav Nutr Phys Act · 2026-Mar-26 The report is an original result of a human Phase III RCT in oncology, but it is a secondary observational analysis (nested within a trial) with a non-drug intervention (physical activity) and non-time-to-event endpoints (physical activity, walking distance). It does not meet the criteria for inclusion as a primary or key secondary efficacy analysis with a time-to-event endpoint and a drug intervention. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. PMID 41880612 · N Engl J Med · 2026-Mar-26 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Randomized trial of low-dose, ultrasound-assisted thrombolysis or heparin for pulmonary embolism. PMID 41610160 · Cardiovasc Res · 2026-Mar-26 未发现恶性肿瘤人群证据。 |
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. PMID 41397287 · Blood · 2026-Mar-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Executive Summary of the American Radium Society Appropriate Use Criteria for Selective Use of Pelvic Radiation Therapy in Locally Advanced Rectal Cancer: A Consensus Statement. PMID 41895479 · Int J Radiat Oncol Biol Phys · 2026-Mar-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095. PMID 41882599 · BMC Cancer · 2026-Mar-25 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of immune-based combinations in metastatic hepatocellular carcinoma: a systematic review and network meta-analysis. PMID 41882593 · BMC Cancer · 2026-Mar-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Protocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery. PMID 41882573 · BMC Cancer · 2026-Mar-25 This is a protocol for a randomized trial in colorectal cancer patients with a synbiotic intervention. It meets criteria for oncology, human, randomized, and drug intervention. However, it is excluded because it is a protocol without results, not explicitly a Phase III trial, and lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as the primary endpoint is quality of life. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study. PMID 41879928 · J Neurol · 2026-Mar-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study. PMID 41879875 · Pituitary · 2026-Mar-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban - Insights From the ONCO DVT Study. PMID 39293971 · Circ J · 2026-Mar-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial. PMID 38462535 · Circ J · 2026-Mar-25 This is a randomized trial in cancer patients with pulmonary embolism, but it compares home vs. in-hospital treatment for rivaroxaban use. The primary endpoint is a composite of clinical events (PE-related death, recurrent VTE, major bleeding) at 3 months, reported as proportions, not as a time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier analysis or hazard ratio. It does not meet the criteria for a definitive oncology efficacy trial with a time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Longitudinal Analysis of Peripheral Blood CD4+ T-Cell Profiles and Clinical Outcomes in Metastatic Non-Small-Cell Lung Cancer Patients Following Bronchoscopic Cryotherapy and Pembrolizumab-Based Therapy. PMID 41977120 · Int J Mol Sci · 2026-Mar-24 The study is a randomized oncology trial with time-to-event endpoints (PFS, OS) and a drug intervention (pembrolizumab). However, the trial phase is not explicitly stated in the provided metadata (e.g., 'Phase III'). The primary objective appears to be immunologic (T-cell profiles) and radiologic response, with survival as secondary endpoints, and the results show no statistical difference in PFS/OS, making it not definitively a Phase III efficacy trial as required. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial. PMID 41877274 · Trials · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase. PMID 41876722 · Osteoporos Int · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Culturally Tailored Mobile Health Intervention to Improve Quality of Life in Black Survivors With Prostate Cancer: Protocol for a Stratified Randomized Controlled Trial. PMID 41875429 · JMIR Res Protoc · 2026-Mar-24 This is a protocol for a randomized controlled trial, not a final results report. The intervention is a mobile health app (non-drug) and standard care. The primary endpoint is quality of life (not a time-to-event endpoint). It lacks explicit phase information, but the description suggests an early-stage intervention trial, not a definitive Phase III study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners. PMID 41873569 · J Oncol Pharm Pract · 2026-Mar-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China. PMID 41872105 · Chin Med J (Engl) · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial. PMID 41564431 · Blood Adv · 2026-Mar-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Antibiotic Therapy for Uncomplicated Acute Appendicitis: Ten-Year Follow-Up of the APPAC Randomized Clinical Trial. PMID 41563747 · JAMA · 2026-Mar-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study. PMID 41499759 · Blood Adv · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Survey Item Wording and Response Options on Prevalence of Beliefs About Nicotine Causing Cancer: A Randomized Survey Experiment. PMID 41405956 · Nicotine Tob Res · 2026-Mar-24 The study is a randomized survey experiment examining how question wording affects public beliefs about nicotine causing cancer. It is not a therapeutic clinical trial in cancer patients, has no drug intervention, and does not report any time-to-event efficacy endpoint like overall survival or progression-free survival. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2. PMID 40884488 · Nicotine Tob Res · 2026-Mar-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| HSK21542 for Postoperative Analgesia in Gynecological Surgery: A Pooled Post-Hoc Analysis of Two Phase III Randomized Controlled Trials. PMID 41874970 · Anesth Analg · 2026-Mar-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. PMID 41870800 · Curr Cardiol Rep · 2026-Mar-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity. PMID 41870723 · Int Ophthalmol · 2026-Mar-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of oral mucositis management based on MASCC/ISOO guidelines in pediatric oncology patients: a randomized controlled trial. PMID 41863643 · Support Care Cancer · 2026-Mar-21 The study is a randomized trial in oncology with original results, but it is not a Phase III/IIIb or Phase II/III trial, does not have a primary time-to-event efficacy endpoint, and the intervention is a non-drug oral care protocol. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. PMID 41765029 · Lancet · 2026-Mar-21 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| [Efficacy of Ganciclovir Combined With Recombinant Human Interferon α-1b for Viral Encephalitis in Children]. PMID 42021910 · Sichuan Da Xue Xue Bao Yi Xue Ban · 2026-Mar-20 The study is a randomized trial in humans with a drug intervention (ganciclovir + interferon), but it investigates viral encephalitis, not a malignant neoplasm (oncology). The primary efficacy endpoints are symptom recovery time, clinical efficacy rate, EEG abnormalities, and biomarkers, none of which are time-to-event endpoints like OS or PFS. Therefore, it is excluded on both oncology and endpoint grounds. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Therapy for Localized Pancreatic Cancer. PMID 41899612 · Cancers (Basel) · 2026-Mar-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer. PMID 41864769 · Eur Urol Oncol · 2026-Mar-20 The study is a randomized controlled trial for non-muscle-invasive bladder cancer reporting recurrence-free survival, which is a time-to-event endpoint. However, it does not meet the eligibility criteria because it is not a Phase III or Phase II/III trial (the phase is not specified as such in the abstract, and the deterministic review indicates it is not a phase 3 trial), and it does not involve a drug-containing intervention as defined for this cohort (the intervention is local chemoresection with mitomycin C, but this is a procedure-based/local therapy rather than a systemic drug intervention eligible for this specific cohort). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Reply to Roberto Contieri, Massimo Lazzeri, Sisto Perdonà, and Rodolfo Hurle's Letter to the Editor re: Kitamura, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 41864759 · Eur Urol · 2026-Mar-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial. PMID 41863008 · Trials · 2026-Mar-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Kin KeeperSM Breast and Cervical Cancer Prevention: An Educational Intervention: A Community-Based Randomized Controlled Trial in Black, Latina, and Arab Women. PMID 41860672 · J Cancer Educ · 2026-Mar-20 The study is a randomized oncology trial in humans with original results, but it lacks a drug intervention and a time-to-event efficacy endpoint. It is an educational prevention study, not a Phase III drug efficacy trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy and safety of anti-VEGF biosimilars compared to reference anti-VEGF agents for neovascular age-related macular degeneration: a systematic review, meta-analysis, and meta-regression. PMID 41860622 · Int Ophthalmol · 2026-Mar-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Testing interventions to increase participation in the Australian National Bowel Cancer Screening Program among persistent never-screeners: study protocol for a randomised controlled trial. PMID 41857651 · Trials · 2026-Mar-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer. PMID 41857556 · BMC Cancer · 2026-Mar-20 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. PMID 41797900 · iScience · 2026-Mar-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. PMID 41734361 · J Clin Oncol · 2026-Mar-20 The record explicitly describes a randomized trial with a drug intervention in oncology (pleural mesothelioma) and reports primary time-to-event efficacy results (OS) with hazard ratios. Although the abstract does not explicitly state the phase, CheckMate 743 is a well-known Phase III trial, and the study's design (randomized, comparative, definitive efficacy endpoint) aligns with Phase III criteria. The report is a long-term follow-up of the original trial results. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 2 Figure · 5 Panel · risk visible |
| Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107). PMID 41719493 · J Clin Oncol · 2026-Mar-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 2 Figure · 2 Panel · risk visible |
| Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study. PMID 41628308 · J Clin Oncol · 2026-Mar-20 The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and is an original result report. However, it is excluded because its primary endpoint is not a time-to-event efficacy endpoint; it reports pharmacodynamic changes (Ki67, ER) rather than OS, PFS, or similar survival outcomes with associated Kaplan-Meier or HR data. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial. PMID 41570275 · J Clin Oncol · 2026-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study. PMID 41093358 · Br J Ophthalmol · 2026-Mar-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14). PMID 41862335 · Eur Urol Oncol · 2026-Mar-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial. PMID 41857036 · Nat Commun · 2026-Mar-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: a protocol of the ALHERT cluster randomised trial. PMID 41856593 · BMJ Open · 2026-Mar-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |